1

2

3
Karl Heinz Altmann, Guido Bold, Pascal Furet, Paul William Manley, Jeanette Marjorie Wood, Stefano Ferrari, Francesco Hofmann, Jürgen Mestan, Andreas Huth, Martin Krüger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl Heinz Thierauch: VEGF receptor tyrosine kinase inhibitors. Novartis, Schering Aktiengesellschaft, Lydia T McNally, George R Dohmann, April 12, 2005: US06878720 (22 worldwide citation)

Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a bicyclic heteroaryl group comprising o ...


4

5
Andreas Steinmeyer, Gunter Neef, Gerald Kirsch, Katica Schwarz, Ruth Thieroff Ekerdt, Herbert Wiesinger, Martin Haberey: 20-position modified pharmaceutically active vitamin D series compounds. Schering Aktiengesellschaft, Millen White Zelano & Branigan P C, December 17, 1996: US05585368 (11 worldwide citation)

The invention relates to vitamin D derivatives, modified in 20-position, of general formula I ##STR1## in which X, Y, Z, R.sub.1, R.sub.2 as well as R.sub.3 have the meaning indicated in the description, process for their production and their use as agents for treatment of hyperproliferative disease ...


6

7
Karl Heinz Altmann, Guido Bold, Pascal Furet, Paul William Manley, Jeanette Marjorie Wood, Stefano Ferrari, Francesco Hofmann, Jürgen Mestan, Andreas Huth, Martin Krüger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl Heinz Thierauch: N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF. Novartis, Schering Aktiengesellschaft, Lydia T McNally, February 21, 2006: US07002022 (10 worldwide citation)

Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R2 is aryl; R2 is a mono- or bicyclic heteroaryl group com ...


8
Andreas Steinmeyer, Gerald Kirsch, Gunter Neef, Katica Schwarz, Ruth Thieroff Ekerdt, Herbert Wiesinger, Martin Haberey: 22-en-25-oxa derivatives in the vitamin D series, process for their production, pharmaceutical preparations containing these derivatives as well as their use as pharmaceutical agents. Schering Aktiengesellschaft, Millen White Zelano & Branigan P C, September 2, 1997: US05663157 (8 worldwide citation)

22-En-24-a-oxa derivatives in the vitamin D series of general formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.4, independently of one another, each mean a hydrogen atom, an alkanoyl group with 1 to 9 carbon atoms or an aroyl group,


9
Werner Skuballa, Bernd Raduechel, Helmut Vorbrueggen, Claus Steffen Stuerzebecher, Martin Haberey, Ekkehard Schillinger, Michael H Town: Novel carbacyclins, processes for their preparation and their use as medicinal agents. Schering Aktiengesellschaft, Millen White & Zelano, May 7, 1991: US05013758 (7 worldwide citation)

(5E)-13,14,18,18,19,19-hexadehydro-3-oxa-6a-carbaprostaglandin I.sub.2 derivatives of Formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 are hydrogen or alkyl of 1-5 carbon atoms, and


10
Martin Krueger, Andreas Huth, Orlin Petrov, Dieter Seidelmann, Karl Heinz Thierauch, Martin Haberey, Andreas Menrad, Alexander Ernst: Anthranyl amides and their use as medicaments. Schering, Miller White Zelano Branigan P C, March 14, 2006: US07012081 (6 worldwide citation)

Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described.